Nemolizumab  (Synonyms: 奈莫利珠单抗; CIM331)

Nemolizumab (CIM331) is a humanized monoclonal antibody that targets the human interleukin-31 receptor a, preventing interleukin-31 (IL-31) from binding to its receptor and the subsequent signaling. Nemolizumab can help reduce itching and sleep disturbances, and it is being studied for atopic dermatitis (AD)^[1][2].

Human IgG2 kappa

Human IgG2 kappa, Isotype Control

Humanized

Nemolizumab (0.01-100 ng/mL, 2 d) 抑制过表达 hIL-31RA/cyIL-31RA 和 OSMR β 的 Ba/F3 细胞对 IL-31 的依赖性增殖^[3]。
Nemolizumab (0.01-100 ng/mL, 2 h 预处理 + 20 min 共孵育) 剂量依赖性地抑制 hIL-31 (30 ng/mL) 诱导的 A549 细胞中 STAT3 磷酸化^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Nemolizumab (40-100 μg/kg, 静脉注射, 急性给药) 阻止了 IL-31 诱导的食蟹猴抓挠行为^[3]。
Nemolizumab (1 mg/kg, 皮下注射, 急性给药) 在第 56 天时，于 6 只实验食蟹猴中的 5 只表现出 1490 ng/mL 的平均血浆浓度，并抑制了从给药后到第 56 天的抓挠行为^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1476039-58-3

液体

Colorless to light yellow

奈莫利珠单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG2 kappa

• 
  Immobilized IL-31R alpha Protein, Human can bind Nemolizumab. The EC₅₀ for this effect is 17.37 ng/mL.

• [1]. Nakahara T, et, al. Nemolizumab and Atopic Dermatitis: the Interaction Between Interleukin-31 and Interleukin-31 Receptor as a Potential Therapeutic Target for Pruritus in Patients With Atopic Dermatitis. 2018;5:405–14.

  [2]. O Nemoto, et al. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2016 Feb;174(2):296-304.  [Content Brief]

  [3]. Oyama S, et al. Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody. Exp Dermatol. 2018 Jan;27(1):14-21.  [Content Brief]